Genentech, Immunocore sign cancer drug deal worth more than $320M

Genentech and Immunocore agreed to use the latter's ImmTAC T-cell receptor technology to discover and develop new cancer targets. The collaboration will center on ImmTACs, which are bispecific biologic drugs designed to recognize intracellular changes during cancer or viral infection. Immunocore could get $10 million to $20 million in initiation fees and more than $300 million in milestone payments per target program plus sales royalties.

View Full Article in:

PharmaTimes (U.K.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI